Radiation-induced normal tissue damage: implications for radiotherapy
Creators
- 1. Radiation Research Program, National Cancer Institute, Bethesda, MD 20892-9727 (United States)
Description
Radiotherapy is an important treatment modality for many malignancies, either alone or as a part of combined modality treatment. However, despite technological advances in physical treatment delivery, patients suffer adverse effects from radiation therapy due to normal tissue damage. These side effects may be acute, occurring during or within weeks after therapy, or intermediate to late, occurring months to years after therapy. Minimizing normal tissue damage from radiotherapy will allow enhancement of tumor killing and improve tumor control and patients quality of life. Understanding mechanisms through which radiation toxicity develops in normal tissue will facilitate the development of next generation radiation effect modulators. Translation of these agents to the clinic will also require an understanding of the impact of these protectors and mitigators on tumor radiation response. In addition, normal tissues vary in radiobiologically important ways, including organ sensitivity to radiation, cellular turnover rate, and differences in mechanisms of injury manifestation and damage response. Therefore, successful development of radiation modulators may require multiple approaches to address organ/site-specific needs. These may include treatments that modify cellular damage and death processes, inflammation, alteration of normal flora, wound healing, tissue regeneration and others, specifically to counter cancer site-specific adverse effects. Further, an understanding of mechanisms of normal tissue damage will allow development of predictive biomarkers; however harmonization of such assays is critical. This is a necessary step towards patient-specific treatment customization. Examples of important adverse effects of radiotherapy either alone or in conjunction with chemotherapy, and important limitations in the current approaches of using radioprotectors for improving therapeutic outcome will be highlighted. (author)
Additional details
Publishing Information
- Publisher
- Institute of Nuclear Medicine and Allied Sciences
- Imprint Place
- Delhi (India)
- Imprint Title
- Proceedings of the international conference on radiation biology: frontiers in radiobiology - immunomodulation, countermeasures and therapeutics: abstract book, souvenir and scientific programme
- Imprint Pagination
- 314 p.
- Journal Page Range
- p. 33
Conference
- Title
- international conference on radiation biology: frontiers in radiobiology - immunomodulation, countermeasures and therapeutics
- Acronym
- ICRB-2014
- Dates
- 11-13 Nov 2014
- Place
- New Delhi (India)
INIS
- Country of Publication
- India
- Country of Input or Organization
- India
- INIS RN
- 46095440
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- DNA DAMAGES; NEOPLASMS; RADIATION DOSES; RADIOPROTECTIVE SUBSTANCES; RADIOTHERAPY
- Descriptors DEC
- DISEASES; DOSES; DRUGS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; RESPONSE MODIFYING FACTORS; THERAPY